Ladenburg Thalmann Downgrades Cempra, Inc. (CEMP) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cempra (CEMP) Sees 21% 'Dead Cat Bounce'
December 30, 2016 10:42 AM ESTAfter plunging 57% on Thursday, Cempra (NASDAQ: CEMP) is making a fierce comeback today. Shares are up 21.2% today to $3.15, helped in part by an upgrade to Equalweight at Morgan Stanley. Morgan Stanley was negative into yesterday plunge on the back of ab FDA CRL for Solithromycin.
... MoreMorgan Stanley Upgrades Cempra, Inc. (CEMP) to Equalweight
December 30, 2016 6:39 AM ESTMorgan Stanley upgraded Cempra, Inc. (NASDAQ: CEMP) from Underweight to Equalweight with a price target of $3.00 (from $5.00) after the FDA issued a CRL on Solithera and the related 57.6% sell-off.
For an analyst ratings summary and ratings history on Cempra, Inc.... More
WBB Securities Downgrades Cempra, Inc. (CEMP) to Hold
December 29, 2016 1:40 PM ESTWBB Securities downgraded Cempra, Inc. (NASDAQ: CEMP) from Strong Buy to Hold with a price target of $4.00 (from $40.00) following today's CRL.
For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.
... MoreMeaningful Commercial role for Cempra's (CEMP) Solithera 'Unlikely' - Needham & Company
December 29, 2016 11:45 AM ESTNeedham & Company analyst Alan Carr reiterated a Hold rating on Cempra, Inc. (NASDAQ: CEMP) after the FDA issued a CRL on Solithera.
Carr commented, "The agency reportedly informed company that safety profile of Solithera has not been adequately characterized and a larger safety... More
Cempra (CEMP) PT Slashed to $2 at Baird Amid CRL
December 29, 2016 9:13 AM ESTBaird analyst Brian Skorney reiterated an Underperform rating and slashed his price target on Cempra, Inc. (NASDAQ: CEMP) to $2.00 (from $6.00) following the FDA CRL.
Skorney commented, "With back-to-back PDUFA dates of the 27th/28th for oral/IV formulations of solithromycin, Cempra finally... More
Cempra (CEMP) Sinks 14% Following FDA CRL on Solithromycin
December 29, 2016 7:02 AM ESTCempra, Inc. (Nasdaq: CEMP) is down 13.9% in pre-open trade Thursday after the company announced that it has received a Complete Response Letter... More
Cempra (CEMP) Receives FDA CRL for Solithromycin NDAs
December 29, 2016 6:57 AM ESTCempra (Nasdaq: CEMP) announced that the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) relating to the companys new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
The CRL states that the FDA cannot approve the NDAs in their present form and notes that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies are required before the NDAs may be... More
